All In MedTech

FDA Clearance Tracker · P170019-S054

FoundationOne CDx

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 16, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jan 16, 2025

Approved

Time to decision

209 days

Received Jun 21, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P170019-S054
Device name
FoundationOne CDx
Applicant location
Boston, MA
Received
Jun 21, 2024
Decided
Jan 16, 2025
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P170019

Device type

Device class
Class III

Every decision under product code PQP

FDA's approval statement

As written in FDA's record.

Approval order to expand the intended use of FoundationOne CDx (F1CDx) to include a companion diagnostic (CDx) indication for the detection of BRAF V600 mutations and BRAF fusions in patients with pediatric low-grade glioma who may benefit from treatment with OJEMDA (tovorafenib).

Source documents

Other decisions for Foundation Medicine, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.